NCT01840436View on ClinicalTrials.gov

Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer

NACompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Oral MucositisCarcinoma in Situ of Upper Respiratory Tract

Interventions

DEVICE

MUCIPLIQ

MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.

DEVICE

Placebo

Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.

Trial Locations (5)

25200

CHRU de Besançon, Site du CH Belfort-Montbéliard, Montbéliard

69373

Centre de Cancérologie Léon Bérard, Lyon

75970

APHP - Hôpital Tenon, Paris

94010

Centre Hospitalier Intercommunal de Créteil, Créteil

94800

Institut de Cancérologie Gustave Roussy, Villejuif

All Listed Sponsors

lead

Organ, Tissue, Regeneration, Repair and Replacement

INDUSTRY

NCT01840436 - Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer | Biotech Hunter | Biotech Hunter